Tolperisone induces UPR-mediated tumor inhibition and synergizes with proteasome inhibitor and immunotherapy by targeting LSD1-Reference-Cited by-同舟云学术

Tolperisone induces UPR-mediated tumor inhibition and synergizes with proteasome inhibitor and immunotherapy by targeting LSD1

Published:2023-09-02 Issue:9 Volume:27 Page:879-895
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Jiang Wei¹,Yang Zhiwei²,Chen Pu¹,Zhao Man¹,Wang Yubo¹,Wang Jingyuan³,Li Xinru¹,Wang Meichen¹,Hou Peng¹

Affiliation:

1. Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China

2. MOE Key Laboratory for Nonequilibrium Synthesis and Modulation of Condensed Matter, Xi’an Jiaotong University, Xi’an, P.R. China

3. Department of Clinical Lab Diagnosis, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China

Funder

National Natural Science Foundation of China

Nature Science Basic Research Program of Shaanxi

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2023.2259097

Reference54 articles.

1. Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics

2. Tolperisone: A Typical Representative of a Class of Centrally Acting Muscle Relaxants with Less Sedative Side Effects

3. Fatal tolperisone poisoning: Autopsy and toxicology findings in three suicide cases

4. Tolperisone-Type Drugs Inhibit Spinal Reflexes via Blockade of Voltage-Gated Sodium and Calcium Channels

5. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease